课题基金 / 基金详情

EFFECT OF ARTERIAL PH ON N-BALANCE OF PATIENTS UNDERGOING AUTOMATED PERITONEAL

EFFECT OF ARTERIAL PH ON N-BALANCE OF PATIENTS UNDERGOING AUTOMATED PERITONEAL
动脉PH值对接受自动化腹膜手术患者N平衡的影响
批准号:
7606172
负责人:
RAJNISH MEHROTRA
金额:
$5.94万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-02-01 至 2007-11-30

项目摘要

项目成果

RAJNISH MEHROTRA的其他基金

相似基金

相关文献

中文摘要
翻译
这个子项目是众多研究子项目之一
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Protein-energy malnutrition (PEM) is a common finding in patients with advanced chronic renal failure and those undergoing maintenance dialysis (MD). The presence of PEM in both incident and prevalent patients with end-stage renal disease portends a poor short- and long-term prognosis. Numerous factors have been identified that appear to play a role in the pathophysiology of PEM in MD patients but four appear to be particularly important: low nutrient intake, systemic inflammation, metabolic acidosis and resistance to the effects of anabolic hormones. There is accumulating evidence that suggests an increase in arterial pH from lower normal to higher normal values may result in improvement in the nutritional status of patients, including those undergoing continuous peritoneal dialysis (CPD). Indeed, a recent report demonstrated that an increase in arterial pH and venous bicarbonate levels from low to high normal values was associated with a decrease in mRNA content of ubiquitin, a protein that plays an important role in the catabolism of skeletal muscle proteins. Even though automated peritoneal dialysis (APD) is the most rapidly growing dialysis modality, very few systematic analyses of nitrogen or protein metabolism of patients undergoing APD have been performed. Given these consideration, we propose to test the following hypothesis: In MD patients undergoing treatment with APD, an arterial pH of 7.43-7.45 is associated with a significantly more positive net protein balance than an arterial pH of 7.36-7.38. To test this hypothesis, we have designed a prospective, randomized crossover metabolic balance study. The proposal has two specific aims. First, we will compare the N-balances in 8 subjects treated with APD at two different levels of arterial blood pH. Second, we will test other secondary hypotheses to study the nutritional consequences of a change in arterial pH within the normal range. Specifically, we will compare (13)C-leucine turnover and examine skeletal muscle biopsies to evaluate the gene and protein expression of selected anabolic proteins (insulin like growth factor I, IGF-I, IGF-II, IGF-I receptor) and gene expression of an anti-anabolic (myostatin) protein. We will make additional assessment of nutritional status at each level of arterial pH; however, we do not anticipate observing any significant changes in the nutritional status or body composition of the subjects because of the short duration of the study. After an initial period of screen and run-in phase, subjects will be hospitalized in the GCRC for a total duration of 41 days. Each phase of arterial pH will last 20 days, and the first pH phase (low or high) will be chosen using a table of random numbers. The diet, physical activity and dialysis prescription will be constant and tightly controlled during the entire study period. The lower arterial pH will be obtained by dialyzing subjects with peritoneal dialysis solution containing 35-mmol/L of lactate with/without supplementation with NH(4)Cl. The higher arterial pH will be obtained by dialyzing subjects with peritoneal dialysis solution containing 40-mmol/L of lactate with/without supplementation with NaHCO(3). Leucine turnover studies, muscle biopsy and nutritional assessment will be performed at the end of each arterial pH phase.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Treatment Options for Insomnia for ESRD
  • 批准号:
    10320851
  • 项目类别:
  • 资助金额:
    $45.02万
  • 财政年份:
    2018
  • 负责人:
    RAJNISH MEHROTRA
  • 依托单位:
Treatment Options for Insomnia for ESRD
  • 批准号:
    10078124
  • 项目类别:
  • 资助金额:
    $65.65万
  • 财政年份:
    2018
  • 负责人:
    RAJNISH MEHROTRA
  • 依托单位:
Biological Determinants of Peritoneal Dialysis Outcomes
  • 批准号:
    9302391
  • 项目类别:
  • 资助金额:
    $65.62万
  • 财政年份:
    2014
  • 负责人:
    RAJNISH MEHROTRA
  • 依托单位:
Biological Determinants of Peritoneal Dialysis Outcomes
  • 批准号:
    8696291
  • 项目类别:
  • 资助金额:
    $64.03万
  • 财政年份:
    2014
  • 负责人:
    RAJNISH MEHROTRA
  • 依托单位:
海外基金